11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts

6. Haemonetics Corporation (NYSE:HAE)

Upside potential: 73.98%

No of hedge funds: 28

A global healthcare company, Haemonetics Corporation (NYSE:HAE) specializes in blood and plasma collection, processing, and transfusion technologies. The company’s core products, automated blood collection systems, surgical cell salvage devices, and plasma separation platforms, have a notable demand among hospitals, blood centers, and plasma providers. Headquartered in Massachusetts, the company thrives in the blood banking and healthcare sector using its data integration capabilities and strong regulatory compliance.

Haemonetics Corporation (NYSE:HAE)’s strong emphasis on efficiency and patient safety increased its position in the industry, leading to 17.09% EPS growth across five years. In its most recent quarter, the company recorded a 4% increase in revenue. Technology upgrades and new long-term agreements with BioLife and Grifols have increased the company’s market share in the U.S. and Europe plasma segment. The divestiture of the whole blood business is expected to provide Haemonetics Corporation (NYSE:HAE) access to resources with higher-margin capabilities, which could translate to a 3-5% revenue growth in 2025.

With 28 hedge funds invested, the company has accumulated moderate institutional interest. Along with a Buy rating, analysts have estimated an upside potential of 73.98%, recognizing Haemonetics Corporation (NYSE:HAE) as one of the best Russell 2000 stocks for investments.